Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation.

Panpan ZhuLuxin YangYibo WuJimin ShiXiaoyu LaiLizhen LiuYishan YeJian YuYanmin ZhaoXiaolin YuanHuarui FuZhen CaiHe HuangYi Luo

Published in: Clinical & translational immunology (2024)

T-cell dose in peripheral blood-derived grafts improves patients' survival with ATG-based myeloablative haplo-HSCT. Younger donors with higher lymphocyte percentages improved patients' survival with an intermediate rDRI risk.

Keyphrases

stem cell transplantation
peripheral blood
end stage renal disease
high dose
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
low dose
free survival
kidney transplantation